Apintyx to move forward with development of NYX-2925
NYX-2925 has received Fast Track designation from the U.S. Food and Drug Administration.
"Our team has evaluated NYX-2925 in multiple models of neurologic conditions, and we see tremendous potential for it to address the unmet need in painful diabetic peripheral neuropathy," Aptinyx CMO Torsten Madsen said. "Patients with this condition struggle to manage their pain effectively with the therapeutic options currently available. Our goal is to complete the Phase 1 study and start a Phase 2 study in 2017. We will also continue to evaluate additional neurologic disorders for which NYX-2925 and other Aptinyx molecules may have clinical applications."
Apintyx has chosen to move forward with the development of NYX-2925 due to results from preclinical studies that support the drug’s use for neuropathic pain. These results will be presented at the 16th World Congress on Pain in Japan.
A Phase 1 trial to assess the safety and patient tolerance of NYX-2925 are underway using healthy volunteers. The trial is randomized, double-blind and placebo-controlled.